Qi‐Nian Wu
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Molecular Biology top 10%
- RNA modifications and cancer
- Circular RNAs in diseases
- Epigenetics and DNA Methylation
Papers in ⓘ
-
- Cancer-related molecular mechanisms research 9
- Cancer Genomics and Diagnostics 4
- Oncology 12
- Cancer Immunotherapy and Biomarkers 5
- Colorectal Cancer Treatments and Studies 3
- Co-authors
- Rui‐Hua Xu (25 shared papers)Huai‐Qiang Ju (17 shared papers)Zexian Liu (19 shared papers)Zhao-Lei Zeng (18 shared papers)Heng‐Ying Pu (7 shared papers)Kun Liao (3 shared papers)Peishan Hu (6 shared papers)Qi Zhao (12 shared papers)
- Journals
- Cancer Letters (3 papers)Cancer Research (2 papers)Nature Communications (2 papers)Gut (2 papers)Signal Transduction and Targeted Therapy (2 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Qi‐Nian Wu
32 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Cancer Research 468
- Molecular Biology 724
- Oncology 240
- Immunology 148
- Pulmonary and Respiratory Medicine 219
Countries citing papers authored by Qi‐Nian Wu
This map shows the geographic impact of Qi‐Nian Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qi‐Nian Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qi‐Nian Wu more than expected).
Fields of papers citing papers by Qi‐Nian Wu
This network shows the impact of papers produced by Qi‐Nian Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qi‐Nian Wu. The network helps show where Qi‐Nian Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Qi‐Nian Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis Hit paper breakdown → | 2022 | 226 |
| 2 | 2011 | 138 | |
| 3 | 2019 | 101 | |
| 4 | 2020 | 79 | |
| 5 | 2023 | 73 | |
| 6 | 2021 | 59 | |
| 7 | 2020 | 46 | |
| 8 | 2023 | 44 | |
| 9 | 2024 | 42 | |
| 10 | 2019 | 38 | |
| 11 | 2022 | 37 | |
| 12 | 2017 | 37 | |
| 13 | 2023 | 30 | |
| 14 | 2021 | 30 | |
| 15 | 2022 | 24 | |
| 16 | 2022 | 16 | |
| 17 | 2012 | 16 | |
| 18 | 2018 | 15 | |
| 19 | 2024 | 14 | |
| 20 | 2017 | 12 |
About Qi‐Nian Wu
Qi‐Nian Wu is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Molecular Biology and Endocrinology, having authored 33 papers that have together received 1.1k indexed citations. Recurring topics across this work include RNA modifications and cancer (13 papers), Cancer-related molecular mechanisms research (9 papers), Cancer Immunotherapy and Biomarkers (5 papers), Genetic factors in colorectal cancer (4 papers), RNA Research and Splicing (4 papers), Cancer Genomics and Diagnostics (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Epigenetics and DNA Methylation (3 papers). The work is most often cited by research in Cancer Research (468 citations), Molecular Biology (724 citations), Oncology (240 citations), Immunology (148 citations) and Pulmonary and Respiratory Medicine (219 citations). Qi‐Nian Wu has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Rui‐Hua Xu, Huai‐Qiang Ju, Zexian Liu, Zhao-Lei Zeng, Heng‐Ying Pu, Kun Liao, Peishan Hu, Qi Zhao, Jin‐Fei Lin and Kai Yu. Their work appears in journals such as Cancer Letters, Cancer Research, Nature Communications, Gut and Signal Transduction and Targeted Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.